CERTIFICATION OF ENROLLMENT
SENATE BILL 6234
Chapter 105, Laws of 2024
68TH LEGISLATURE
2024 REGULAR SESSION
BRANCHED-CHAIN KETOACID DEHYDROGENASE KINASE DEFICIENCY—NEWBORN SCREENING
EFFECTIVE DATE: June 6, 2024
Passed by the Senate February 7, 2024 Yeas 48 Nays 0 DENNY HECK
President of the Senate Passed by the House February 27, 2024 Yeas 96 Nays 0 LAURIE JINKINS
Speaker of the House of Representatives | CERTIFICATE I, Sarah Bannister, Secretary of the Senate of the State of Washington, do hereby certify that the attached is SENATE BILL 6234 as passed by the Senate and the House of Representatives on the dates hereon set forth. SARAH BANNISTER
Secretary Secretary |
Approved March 14, 2024 11:44 AM | FILED March 14, 2024 |
JAY INSLEE
Governor of the State of Washington | Secretary of State State of Washington |
SENATE BILL 6234
Passed Legislature - 2024 Regular Session
State of Washington | 68th Legislature | 2024 Regular Session |
BySenators L. Wilson, Hasegawa, and Lovick
Read first time 01/15/24.Referred to Committee on Health & Long Term Care.
AN ACT Relating to screening newborn infants for branched-chain ketoacid dehydrogenase kinase deficiency; creating new sections; and providing an expiration date.
BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF WASHINGTON:
NEW SECTION. Sec. 1. The legislature finds that there is promising research that individuals with branched-chain ketoacid dehydrogenase kinase deficiency, which is linked to neurodevelopmental disorders including autism spectrum disorder, can potentially benefit significantly from early diagnosis and treatment. The legislature intends to engage the state board of health to conduct an evaluation of whether branched-chain ketoacid dehydrogenase kinase deficiency screening should be added to the newborn screening panel.
NEW SECTION. Sec. 2. (1) The state board of health shall consider whether or not to add the branched-chain ketoacid dehydrogenase kinase deficiency screening to the mandatory newborn screening panel as required in RCW 70.83.020. The state board of health shall submit to the governor and the appropriate committees of the legislature a report no later than June 30, 2025, that includes a summary of the evaluation conducted in this section and the findings and recommendations on the addition of the branched-chain ketoacid dehydrogenase kinase deficiency screening to the mandatory newborn screening panel. (2) This section expires July 30, 2026.
Passed by the Senate February 7, 2024.
Passed by the House February 27, 2024.
Approved by the Governor March 14, 2024.
Filed in Office of Secretary of State March 14, 2024.
--- END ---